By Janis Naeve, Venture Partner at Cota Capital
AI, machine learning (ML), and CRISPR are revolutionizing drug development in the pharmaceutical industry. From 2019 to 2022, over $9 billion was invested in ML-enabled drug discovery start-ups to streamline the R&D process. After his post-doctoral fellowship with Nobel Laureate Dr. Jennifer Doudna, Dr. Chun-Hao Huang founded Algen Biotechnologies.
In this webinar, Cota Capital Venture Partner Janis Naeve, Ph.D., and special guest Dr. Chun-Hao Huang, Ph.D., Co-Founder and CEO of Algen Biotechnologies, discuss how Algen incorporates these advanced technologies to reach scaled causal biology and reverse engineering disease trajectories, aiming to discover novel therapeutics and best-in-class molecules.
ABOUT COTA ACCESS
The Cota Access webinar series offers in-depth, market-driven discussions from featured founders, thought leaders, and leading executives, exploring cutting-edge business and technology trends that fundamentally impact enterprises.
Learn more about Algen Biotechnologies: https://www.algenbio.com/
